Month: October 2023

Is Bitcoin Primed for a Resurgence? BTC Tops $35,000

Posted on by cpatches

In a recent rally, Bitcoin briefly surpassed the $35,000 mark, marking a significant milestone not seen since May 2022. This resurgence has breathed new life into the world’s foremost cryptocurrency and left many wondering if Bitcoin is poised for a remarkable comeback.

A Rally of Remarkable Proportions:

The year 2023 has unfolded with tremendous vigor for Bitcoin enthusiasts. The cryptocurrency has ascended over 100% since the year’s inception, igniting optimism among investors and speculators alike. This remarkable rally could, in part, be attributed to a phenomenon known as a “short squeeze.” In essence, some investors who had bet against Bitcoin found themselves in a precarious position, compelled to buy Bitcoin to cover their short positions, thus driving its price higher.


Short Liquidations and Regulatory Hopes:

A staggering $167 million in short liquidations, predominantly on offshore exchanges, serves as evidence of the short squeeze’s impact. However, the Bitcoin market’s dynamics extend beyond short-term speculation. The recent decision by the U.S. Securities and Exchange Commission (SEC) not to appeal a ruling in Grayscale’s lawsuit has sparked optimism in the cryptocurrency community. The hope is that this decision could pave the way for the approval of a Bitcoin-related exchange-traded fund (ETF) in the coming months. Momentum has been building as firms vying for a Bitcoin ETF updated their filings, and prominent investors such as Ark’s Cathie Wood and Galaxy’s Mike Novogratz have highlighted a shift in the SEC’s tone. The regulatory body appears to be engaging more positively with the cryptocurrency industry, increasing the odds of a Bitcoin ETF receiving the green light.

The Significance of a Bitcoin ETF:

A Bitcoin ETF would represent a pivotal development for both seasoned and novice investors. It would provide a structured and regulated way for individuals to gain exposure to Bitcoin’s price movements without the need to directly own the cryptocurrency. Such an ETF could bridge the gap between traditional financial markets and the digital asset realm, further legitimizing Bitcoin as a viable investment.

Bitcoin’s Checkered History:

To understand the significance of this potential resurgence, it’s crucial to reflect on Bitcoin’s journey. Since its inception in 2009, Bitcoin has weathered numerous storms, experiencing extreme volatility and wild price swings. It reached its all-time high of nearly $65,000 in April 2021 before experiencing a sharp decline.

Regulatory Scrutiny and Industry Challenges:

Bitcoin and the broader cryptocurrency industry have faced increasing regulatory scrutiny in recent years. The high-profile FTX bankruptcy case and Terraform’s legal troubles, where they are charged with defrauding investors, serve as stark reminders of the challenges the industry faces. Furthermore, the SEC has been actively cracking down on cryptocurrency companies. Firms like Coinbase and Ripple are currently embroiled in legal battles with the SEC, accused of violating securities laws. These legal skirmishes, along with others in the crypto space, have underscored the pressing need for regulatory clarity in the United States. As the industry navigates these challenges, the question that looms is whether Bitcoin is indeed primed for a resurgence. The recent rally, the prospects of a Bitcoin ETF, and the evolving regulatory landscape all point to a cryptocurrency with the potential for a triumphant return, promising exciting times ahead for Bitcoin enthusiasts and investors.

UAW Strike Escalates as GM’s Strong Earnings Raise the Stakes

Posted on by cpatches

The United Auto Workers (UAW) strike against General Motors (GM) has escalated, now including a full-size SUV plant in Texas. The latest developments unfolded just hours after GM reported third-quarter earnings that exceeded Wall Street’s expectations, underscoring the high-stakes nature of the ongoing labor dispute.

Approximately 5,000 workers at GM’s Arlington Assembly plant, responsible for producing full-size Cadillac, GMC, and Chevrolet SUVs, have joined the strike action, amplifying the economic impact of the labor unrest.

GM’s Earnings Report and Ongoing Strike Impact:

General Motors’ robust third-quarter performance showcased adjusted earnings per share of $2.28, surpassing the estimated $1.88. Revenue also exceeded expectations, with GM reporting $44.13 billion against the anticipated $43.68 billion.

However, the labor strike, which commenced on September 15 and has intensified since then, has cast a shadow over GM’s otherwise impressive financial results. The strikes have proven costly, with GM estimating a loss of around $200 million per week due to disrupted production.

The volatility caused by the ongoing strikes has prompted GM to withdraw its previously announced earnings guidance for the year. Furthermore, the company has adjusted its near-term targets for electric vehicles (EVs), citing slower-than-expected demand for electric vehicles.

UAW’s Stance and Worker Impact:

UAW President Shawn Fain has been steadfast in the union’s demands during the labor dispute, emphasizing the principle of equitable compensation for GM workers. In a statement, Fain noted, “Another record quarter, another record year. As we’ve said for months: record profits equal record contracts. It’s time GM workers, and the whole working class, get their fair share.”

With over 45,000 UAW members at Detroit automakers currently on strike, which constitutes roughly 31% of union members covered by expired contracts, the strike has already left a considerable impact. Additionally, around 7,000 workers, approximately 5% of the workforce, have been laid off due to the ripple effects of the strikes, according to the affected companies.

It’s worth noting that this recent escalation of the strike was initially planned earlier in the month, but GM proposed a last-minute inclusion of workers at the company’s joint-venture battery cell plants in the master agreement, leading to a temporary pause in strike activities. However, recent developments suggest that progress in negotiations may have stalled, reigniting tensions between the UAW and GM.

The ongoing UAW strike against General Motors, coupled with GM’s impressive earnings report and its subsequent decision to withdraw guidance due to the labor unrest, highlights the delicate balance between corporate success and labor demands in the auto industry. As negotiations continue, the stakes remain high for both the automaker and its dedicated workforce.

Release – FAT Brands to Announce Third Quarter 2023 Financial Results On October 26, 2023

Posted on by aweinsoff@channelchek.com

Research News and Market Data on FAT

October 23, 2023

Download(opens in new window)

LOS ANGELES, Oct. 23, 2023 (GLOBE NEWSWIRE) — FAT (Fresh. Authentic. Tasty.) Brands Inc. (NASDAQ: FAT) (“FAT Brands” or the “Company”), a leading global franchising company and parent company of iconic brands including Round Table Pizza, Fatburger, Johnny Rockets, Twin Peaks, Fazoli’s and 13 other restaurant concepts, today announced that the Company will host a conference call to review its third quarter 2023 financial results on Thursday, October 26, 2023 at 4:30 PM ET. A press release with third quarter 2023 financial results will be issued prior to the conference call that day.

The conference call can be accessed live over the phone by dialing 1-844-826-3035 from the U.S. or 1-412-317-5195 internationally. A replay will be available after the call until Thursday, November 16, 2023, and can be accessed by dialing 1-844-512-2921 from the U.S. or 1-412-317-6671 internationally. The passcode is 10183290. Hosting the call will be Andy Wiederhorn, Chairman, and Ken Kuick, Co-Chief Executive Officer and Chief Financial Officer.

The conference call will also be webcast live from the corporate website at www.fatbrands.com, under the “Investors” section. A replay of the webcast will be available through the corporate website shortly after the call has concluded.

About FAT (Fresh. Authentic. Tasty.) Brands

FAT Brands (NASDAQ: FAT) is a leading global franchising company that strategically acquires, markets, and develops fast casual, quick-service, casual dining, and polished casual dining concepts around the world. The Company currently owns 18 restaurant brands: Round Table Pizza, Fatburger, Marble Slab Creamery, Johnny Rockets, Fazoli’s, Twin Peaks, Great American Cookies, Hot Dog on a Stick, Buffalo’s Cafe & Express, Hurricane Grill & Wings, Pretzelmaker, Smokey Bones, Elevation Burger, Native Grill & Wings, Yalla Mediterranean and Ponderosa and Bonanza Steakhouses, and franchises and owns over 2,300 units worldwide. For more information on FAT Brands, please visit www.fatbrands.com.

Investor Relations:
ICR
Michelle Michalski
IR-FATBrands@icrinc.com
646-277-1224

Media Relations:
Ali Lloyd
alloyd@fatbrands.com
435-760-6168

###

Source: FAT Brands Inc.

Release – PDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMO

Posted on by aweinsoff@channelchek.com

Research News and Market Data on PDSB

  • Combination of PDS0101 and KEYTRUDA® appears to lead to changes towards a TH1 predominant cytokine profile reported to be associated with improved killer T cell activity
  • Lowered CD8 T cells in peripheral blood after treatment align with previously reported CD8 T cell targeting and accumulation in tumors1

PRINCETON, N.J., Oct. 23, 2023 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (PDS Biotech or the Company), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary T cell activating platforms, today announced immune response data from a preliminary analysis of a subset of patients in VERSATILE-002, the Phase 2 clinical trial evaluating the safety and efficacy of PDS0101 in combination with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with human papillomavirus (HPV)16-positive recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The data presented during the European Society for Medical Oncology Congress 2023 (ESMO Congress 2023) provided preliminary insight to the pre-existing immune responses in advanced HPV-positive HNSCC patients and potential changes to the immune profile after treatment.

“Generation of multifunctional, anti-tumor T cells with the relevant cytokine and chemokine profiles are necessary for effective long-term control of tumor growth and clinical outcomes. This initial study focused on understanding the immunological profile of advanced head and cancer patients in the blood,” said Kevin Harrington, PhD, Professor of Biological Cancer Therapies, The Royal Marsden. “This preliminary study suggests that PDS0101 may promote a TH1 predominant cytokine profile as well as induction of important T cell activating chemokines. Such studies could be helpful in providing further insight into how PDS0101 in combination with KEYTRUDA® alters T cell cytokine and chemokine profiles to promote improved clinical outcomes.”

The data presented at ESMO 2023 included 18 patients with a median age of 63 years (range 46-83) and all had confirmed HPV16-positive tumors. The immunological profiles were assessed at three timepoints: pre-treatment,12 (cycle 5), and 36 weeks (cycle 13) following four and five cycles of combination therapy, respectively.

Highlights of the analysis include:

  • Combination of PDS0101 and KEYTRUDA® appears to lead to changes towards a TH1 predominant cytokine profile reported to be associated with improved killer T cell activity
  • Combination of PDS0101 and KEYTRUDA® resulted in increased polyfunctionality reflected in T cells expressing 5 or more cytokines. Increased polyfunctionality is typically associated with enhanced killing function and anti-tumor activity

“This analysis provides preliminary insights into how PDS0101 in combination with KEYTRUDA® may be impacting specific cytokines and chemokines in CD8 and CD4 T cell populations,” said Lauren V. Wood, MD, Chief Medical Officer of PDS Biotech. “The investigational combination appears to be promoting a predominant TH1 immunologic profile that is associated with decreases in CD8 T cells in peripheral blood. We are encouraged that these observations align with other Phase 2 studies reporting PDS0101-induced polyfunctional CD8 T cells traffic to tumors and we look forward to continued investigation in our VERSATILE-003 Phase 3 study.”

1 Klopp A, et al. 2022. IMMUNOCERV, an ongoing Phase II trial combining PDS0101, an HPV-specific T cell immunotherapy, with chemotherapy and radiation for treatment of locally advanced cervical cancers. Presented at: Society for Immunotherapy of Cancer; November 8-12, 2022. Boston, MA. Abstract: 674.

About PDS0101
PDS0101, PDS Biotech’s lead candidate, is a novel investigational human papillomavirus (HPV)-targeted immunotherapy that stimulates a potent targeted T cell attack against HPV-positive cancers. PDS0101 is given by subcutaneous injection alone or in combination with other immunotherapies and cancer treatments. In a Phase 1 study of PDS0101 in monotherapy, the treatment demonstrated the ability to generate multifunctional HPV16-targeted CD8 and CD4 T cells with minimal toxicity. Interim data suggests PDS0101 generates clinically active immune responses and the combination of PDS0101 with other treatments can demonstrate significant disease control by reducing or shrinking tumors, delaying disease progression, and/or prolonging survival. The combination of PDS0101 with other treatments does not appear to compound the toxicity of other agents.

About VERSATILE-002
VERSATILE-002 is a single-arm Phase 2 trial evaluating the safety and efficacy of PDS0101, an HPV16-targeted investigational T cell-activating immunotherapy that leverages PDS Biotech’s proprietary Versamune® technology, in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). The combination is being evaluated in immune checkpoint inhibitor (ICI)-naïve and ICI-refractory patients with recurrent/metastatic HPV16-positive head and neck squamous cell carcinoma (HNSCC) and was granted Fast Track designation by the Food and Drug Administration in June 2022.

About PDS Biotechnology
PDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on our proprietary Versamune®, Versamune® plus PDS0301, and Infectimune® T cell-activating platforms. We believe our targeted immunotherapies have the potential to overcome the limitations of current immunotherapy approaches through the activation of the right type, quantity and potency of T cells. To date, our lead Versamune® clinical candidate, PDS0101, has demonstrated the ability to reduce and shrink tumors and stabilize disease in combination with approved and investigational therapeutics in patients with a broad range of HPV16-associated cancers in multiple Phase 2 clinical trials and will be advancing into a Phase 3 clinical trial in combination with KEYTRUDA® for the treatment of recurrent/metastatic HPV16-positive head and neck cancer in 2023. Our Infectimune® based vaccines have also demonstrated the potential to induce not only robust and durable neutralizing antibody responses, but also powerful T cell responses, including long-lasting memory T cell responses in pre-clinical studies to date. To learn more, please visit www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

Forward Looking Statements
This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for PDS0101, PDS0203 and other Versamune® and Infectimune® based product candidates; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS0101, PDS0203 and other Versamune® and Infectimune® based product candidates and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund its disclosed clinical trials, which assumes no material changes to the Company’s currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. 

Versamune® and Infectimune® are registered trademarks of PDS Biotechnology Corporation. KEYTRUDA® is a registered trademark of Merck Sharp and Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, N.J., USA.

Investor Contact:
Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
Email: pdsb@cg.capital

Media Contact:
Gina Cestari
6 Degrees
Phone: +1 (917) 797-7904
Email: gcestari@6degreespr.com

Release – Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer

Posted on by aweinsoff@channelchek.com

Research News and Market Data on ELDN

IRVINE, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced the appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer with responsibility for leading the company’s clinical development programs.

“We are pleased to welcome Dr. Katz to the Eledon team,” said David-Alexandre C. Gros, M.D., Eledon Chief Executive Officer. “Dr. Katz brings a wealth of knowledge in the surgical transplantation field together with extensive experience designing and overseeing clinical trials for immunosuppressive treatments. We look forward to his leadership and contributions as we continue to advance tegoprubart for the prevention of rejection in patients undergoing transplantation procedures.”

Dr. Katz is an experienced transplant surgeon with significant clinical development experience. Most recently, he was Chief Medical Officer at eGenesis where he helped lead the clinical development of eGenesis’ xenotransplantation programs. Prior to eGenesis, Dr. Katz was Vice President of Clinical Development first at Viela Bio and then at Horizon Therapeutics following its acquisition of Vielo Bio. At Horizon and Viela Bio, Dr. Katz led the clinical development of inebilizumab in multiple autoimmune indications and oversaw the regulatory submission and approval of UPLIZNA®(inebilizumab) to treat neuromyelitis optica spectrum disorder in adults.

Prior to Viela Bio, Dr. Katz served as Senior Director of Clinical Development at MedImmune Inc. where he oversaw the clinical development of three different biologics. Prior to MedImmune, Dr. Katz served as Senior Director of Transplantation with the Medicine Development Group at Pfizer. At Pfizer, he oversaw multiple research programs with rapamycin, an anti-rejection drug, and was instrumental in the regulatory submission and FDA approval of rapamycin as a treatment for lymphangioleiomyomatosis (LAM), a rare and fatal lung disease.

Before joining industry, Dr. Katz spent two decades as a transplant surgeon. He was director of the abdominal transplantation division at Integris Baptist Medical Center in Oklahoma City, and an associate professor of surgery and the director of the liver transplantation division at the University of Massachusetts Medical Center, Worcester, MA. Dr. Katz spearheaded liver transplantation advances at these institutions and was actively involved with policy making in organ donation and allocation. Dr. Katz earned his M.D. at Hadassah Hebrew University Medical School in Jerusalem.

“With tegoprubart, Eledon is well positioned to meet the critical need for innovative transplantation immunosuppressant therapies,” said Dr. Katz. “I’m excited to join Eledon as the company continues to realize its vision to significantly improve the functional life of transplanted organs and address the side effects of current immunosuppressive treatments.”

About Eledon Pharmaceuticals and tegoprubart

Eledon Pharmaceuticals is a clinical stage biotechnology company with immunology expertise that is developing therapies to protect and prevent rejection of transplanted organs, as well as to treat amyotrophic lateral sclerosis (ALS). The Company’s lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target with broad therapeutic potential. Eledon is headquartered in Irvine, California. For more information, please visit the company’s website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter

Investor Contact:

Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com

Media Contact:

Jenna Urban
Berry & Company Public Relations
(212) 253 8881
jurban@berrypr.com

Source: Eledon Pharmaceuticals

Release – Alvopetro Publishes 2022 Sustainability Report

Posted on by aweinsoff@channelchek.com

Research News and Market Data on ALVOF

Oct 23, 2023

CALGARY, AB, Oct. 23, 2023 /CNW/ – Alvopetro Energy Ltd. (TSXV: ALV) (OTCQX: ALVOF) is pleased to announce the release of our 2022 Sustainability Report (the “Report”), highlighting our approach to environmental, social and governance (“ESG”) practices for the year ended December 31, 2022 and outlining our commitment to building a sustainable future for all of our stakeholders. A full copy of the Report, which was approved by Alvopetro’s Board of Directors, can be found on our website at https://alvopetro.com/Sustainability.

2022 ESG highlights included:

  • Natural gas focused production (96% of total 2022 production);
  • Alvopetro’s locally produced natural gas resulted in average savings of 57% for consumers relative to imported LNG;
  • Maintained low emission intensity with Scope 1 & 2 emissions intensity of 7.4 kg CO2e per boe;
  • No reported environmental spills;
  • Zero lost-time safety incidents;
  • 33% of our total workforce and 38% of our senior leadership team positions are held by women;
  • Strengthened commitment to biodiversity and conservation with our northeastern collared sloth conservation program;
  • Expanded social investment programs to benefit over 600 recipients, increasing spending by 156% ; and,
  • With increased production and cash flows, we paid over $20 million in royalties, income taxes and sales taxes, contributing to direct and indirect benefits for the communities we operate and to Brazil as a whole.

Corporate Presentation

Alvopetro’s updated corporate presentation is available on our website at:http://www.alvopetro.com/corporate-presentation. 

Social Media

Follow Alvopetro on our social media channels at the following links:

Twitter – https://twitter.com/AlvopetroEnergyInstagram – https://www.instagram.com/alvopetro/LinkedIn – https://www.linkedin.com/company/alvopetro-energy-ltdYouTube –https://www.youtube.com/channel/UCgDn_igrQgdlj-maR6fWB0w

Alvopetro Energy Ltd.’s vision is to become a leading independent upstream and midstream operator in Brazil. Our strategy is to unlock the on-shore natural gas potential in the state of Bahia in Brazil, building off the development of our Caburé and Murucututu natural gas fields and our strategic midstream infrastructure.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

All amounts contained in this new release are in United States dollars, unless otherwise stated and all tabular amounts are in thousands of United States dollars, except as otherwise noted.

Forward-Looking Statements and Cautionary Language. This news release contains “forward-looking information” within the meaning of applicable securities laws. The use of any of the words “will”, “expect”, “intend” and other similar words or expressions are intended to identify forward-looking information. Forward‐looking statements involve significant risks and uncertainties, should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether or not such results will be achieved. A number of factors could cause actual results to vary significantly from the expectations discussed in the forward-looking statements. These forward-looking statements reflect current assumptions and expectations regarding future events. Accordingly, when relying on forward-looking statements to make decisions, Alvopetro cautions readers not to place undue reliance on these statements, as forward-looking statements involve significant risks and uncertainties. More particularly and without limitation, this news release contains forward-looking information concerning Alvopetro’s approach to ESG practices and plans for the future. The forward‐looking statements are based on certain key expectations and assumptions made by Alvopetro, including but not limited to expectations and assumptions concerning the success of future drilling, completion, testing, recompletion and development activities, equipment availability, the timing of regulatory licenses and approvals, the outlook for commodity markets and ability to access capital markets, the impact of global pandemics and other significant worldwide events, the performance of producing wells and reservoirs, well development and operating performance, foreign exchange rates, general economic and business conditions, weather and access to drilling locations, the availability and cost of labour and services, environmental regulation, including regulation relating to hydraulic fracturing and stimulation, the ability to monetize hydrocarbons discovered, expectations regarding Alvopetro’s working interest and the outcome of any redeterminations, the regulatory and legal environment and other risks associated with oil and gas operations. The reader is cautioned that assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be incorrect. Actual results achieved during the forecast period will vary from the information provided herein as a result of numerous known and unknown risks and uncertainties and other factors.  Although Alvopetro believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because Alvopetro can give no assurance that it will prove to be correct. Readers are cautioned that the foregoing list of factors is not exhaustive. Additional information on factors that could affect the operations or financial results of Alvopetro are included in our annual information form which may be accessed on Alvopetro’s SEDAR+ profile at www.sedarplus.ca. The forward-looking information contained in this news release is made as of the date hereof and Alvopetro undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

SOURCE Alvopetro Energy Ltd.

Release – Schwazze Announces Launch of Standing Akimbo Hotspot, A New Store Within A Store Concept In Fort Collins

Posted on by aweinsoff@channelchek.com

Research News and Market Data on SHWZ

October 20, 2023

PDF Version

FORT COLLINS, Colo., Oct. 20, 2023 /CNW/ – Medicine Man Technologies, Inc., operating as Schwazze, (OTCQX: SHWZ) (NEO: SHWZ) (“Schwazze” or the “Company”), today announced a first of its kind store-within-a-store model in Fort Collins, combining a Star Buds neighborhood dispensary with a Standing Akimbo Hotspot, bringing together two innovative retailers that operate within the trusted Schwazze house of brands.

   

Star Buds, established in 2013, has a standing reputation for the widest selection, top quality products, and stellar service. Star Buds’ treasure chest of offerings along with the Gratify Rewards Program allows shoppers to save on every purchase across a huge selection of recreational products.

Standing Akimbo, established in 2015, is Colorado’s most recognized medical cannabis dispensary. Located in Denver and Colorado Springs, its team of passionate customer service representatives celebrate Colorado’s medical marijuana market through a warehouse service model with value prices.

Now, Standing Akimbo has partnered with Star Buds in Fort Collins to operate Colorado’s first store-within-a-store model.

Collin Lodge, President of Retail for Schwazze, believes the dual banner strategy introduces a new level of convenience that the cannabis market has not seen. “Star Buds and Standing Akimbo are two trusted brands. When we surveyed our Northern Colorado customers, they wanted both Star Buds and Standing Akimbo. Our new Fort Collins store-within-a-store model is just a lesson in listening to our customer base. This new dispensary concept is all about meeting the customer where they want us to be.”

Star Buds Fort Collins is open from 8:00 AM – 10:00 PM seven days a week. Stop by Star Buds with the new Standing Akimbo Hotspot in Fort Collins, at 5740 S College Ave UNIT A, Fort Collins, CO 80525 or visit www.starbudscolorado.com and standingakimbo.com for more information.

About Schwazze

Schwazze (OTCQX: SHWZ) (NEO: SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to take its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale.

Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector.

Medicine Man Technologies, Inc. was Schwazze’s former operating trade name. The corporate entity continues to be named Medicine Man Technologies, Inc. Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth. To learn more about Schwazze, visit www.schwazze.com.

Forward-Looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “plan,” “will,” “may,” “continue,” “predicts,” or similar words. Forward-looking statements are not guarantees of future events or performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified. Consequently, actual events and results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; (v) difficulties in securing regulatory approval to market our products and product candidates; (vi) our ability to successfully execute our growth strategy in Colorado and outside the state, (vii) our ability to consummate the acquisition described in this press release or to identify and consummate future acquisitions that meet our criteria, (viii) our ability to successfully integrate acquired businesses, including the acquisition described in this press release, and realize synergies therefrom, (ix) the ongoing COVID-19 pandemic, * the timing and extent of governmental stimulus programs, and (xi) the uncertainty in the application of federal, state and local laws to our business, and any changes in such laws. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.

   

View original content to download multimedia:https://www.prnewswire.com/news-releases/schwazze-announces-launch-of-standing-akimbo-hotspot-a-new-store-within-a-store-concept-in-fort-collins-301963604.html

SOURCE Schwazze

Direct Digital Holdings (DRCT) – Investor Meeting Highlights

Posted on by cpereira@noblefcm.com


Monday, October 23, 2023

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Highlights from investor meetings. This report provides highlights from a non-deal roadshow with investors last week in New York, Miami, and Boca Raton with Keith Smith, Co-Founder and President, and Diana Diaz, Chief Financial Officer. 

Reiterating full year guidance. Management appeared sanguine about at least hitting expectations on revenue and operating cash flow (adj. EBITDA) for the full year 2023. Revenues are expected to increase roughly 43% to $128.1 million, in line with management’s guidance. Adj. EBITDA in 2023 is expected to be $9.0 million, growing 25% to $11.3 million in 2024.  


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Chevron Agrees to Buy Hess in $53 Billion Mega-Merger

Posted on by cpatches

In a significant move that underscores the ongoing transformation within the energy sector, Chevron (NYSE: CVX) has recently announced its acquisition of Hess (NASDAQ: HES) in a monumental $53 billion all-stock deal. This mega-merger comes on the heels of Exxon Mobil’s $60 billion bid for Pioneer Natural Resources, marking the second colossal consolidation among major U.S. oil players this month.

The strategic significance of this merger revolves around the ambitions of both Chevron and Exxon to unlock the untapped potential of Guyana’s burgeoning oil industry. Guyana, once an inconspicuous player in the oil sector, has rapidly ascended the ranks to become one of Latin America’s foremost oil producers, second only to industry giants Brazil and Mexico, thanks to substantial oil discoveries in recent years.

This high-stakes deal positions Chevron in direct competition with its formidable rival, Exxon, in the race to capitalize on Guyana’s newfound prominence. Chevron’s offer, consisting of 1.025 of its shares for each share of Hess or $171 per share, represents a premium of approximately 4.9% to the stock’s most recent closing price. The total value of the transaction, encompassing debt, amounts to a staggering $60 billion.

Upon the successful completion of this transaction, John Hess, CEO of Hess Corp, is set to join Chevron’s board of directors, cementing the collaborative vision of the two energy giants. Chevron has also expressed its commitment to fortify its share repurchase program, intending to bolster it by an additional $2.5 billion, reaching the upper limit of its annual $20 billion range. This decision underscores Chevron’s confidence in future energy prices and its robust cash generation.

Notably, this merger serves as a testament to Chevron’s unwavering dedication to fossil fuels. In a climate where global energy dynamics are evolving rapidly, Chevron’s move underscores a resolute belief in the enduring strength of oil demand. Large energy producers continue to employ acquisitions as a strategy to replenish their reserves after years of underinvestment, further highlighting the industry’s drive to secure its future in a dynamically shifting landscape.

This merger between Chevron and Hess not only signals the industry’s determination to harness the full potential of Guyana’s oil reserves but also represents a pivotal moment in the evolution of the energy sector, as established players seek new avenues for growth and consolidation in a rapidly changing world. The deal is expected to close around the first half of 2024, setting the stage for a new chapter in the energy industry’s ongoing narrative.

10-Year Treasury Yield Surpasses 5%: Implications for Markets, Investors, and Beyond

Posted on by cpatches

The yield on the 10-year Treasury note has once again crossed the 5% threshold. This benchmark yield has far-reaching implications for both the financial markets and the general public, serving as a barometer of economic conditions and influencing investment decisions, interest rates, and the cost of borrowing for governments, businesses, and individuals.

Source: U.S. Department of the Treasury
Data as of Oct. 20, 2023

Why Does the 10-Year Treasury Yield Matter?

The 10-year Treasury yield is a crucial indicator of the economy’s health and the state of the financial markets. It reflects the interest rate that the U.S. government pays on its debt with a 10-year maturity, which is considered a relatively safe investment. As such, it provides a reference point for other interest rates in the financial system.

Impact on Investors:

  • Fixed-Income Investments: The 10-year Treasury yield directly impacts the pricing and performance of bonds and other fixed-income investments. When the yield rises, the value of existing bonds tends to decrease, which can lead to capital losses for bondholders.
  • Stock Market: Higher Treasury yields can put pressure on stock prices. As bond yields increase, investors may shift from equities to bonds in search of better returns with lower risk. This shift can lead to stock market volatility and corrections.
  • Cost of Capital: Rising Treasury yields can increase the cost of capital for businesses. This may result in higher borrowing costs for companies, which can impact their profitability and, subsequently, their stock prices.

Impact on the General Public:

  • Mortgage Rates: Mortgage rates are closely tied to the 10-year Treasury yield. When yields rise, mortgage rates tend to follow suit. As a result, homebuyers may face higher borrowing costs, potentially limiting their ability to purchase homes or leading to higher monthly payments for existing homeowners with adjustable-rate mortgages.
  • Consumer Loans: The yield on the 10-year Treasury note also influences interest rates for various consumer loans, including auto loans and personal loans. When yields rise, the cost of borrowing for individuals increases, affecting their spending capacity.
  • Inflation Expectations: An increase in the 10-year Treasury yield can signal rising inflation expectations. In response, consumers may anticipate higher prices for goods and services, which can impact their spending and savings decisions.
  • Retirement and Savings: For retirees and savers, rising Treasury yields can be a mixed bag. While it can translate into higher returns on savings accounts and CDs, it can also result in increased volatility in investment portfolios, which may be a concern for those relying on their investments for income.

Market Sentiment and Economic Outlook:

A sustained rise in the 10-year Treasury yield is often seen as an indication of a strengthening economy. However, if the yield surges too quickly, it can raise concerns about the pace of economic growth and the potential for the Federal Reserve to implement tighter monetary policy to combat inflation.

In conclusion, the 10-year Treasury yield is not just a number on a financial ticker; it’s a critical metric that touches the lives of investors, borrowers, and everyday consumers. Its movements provide valuable insights into the state of the economy and financial markets, making it a figure closely watched by experts and the public alike.

INVO Bioscience and NAYA Biosciences Announce Definitive Merger Agreement

Posted on by cpatches

INVO Bioscience (NASDAQ: INVO) and NAYA Biosciences have unveiled a definitive merger agreement. The primary objective of this union is to establish a robust, publicly traded life science conglomerate with a shared mission: to enhance patient access to life-altering treatments in the fields of oncology, fertility, and regenerative medicine.

The newly formed entity, to be known as “NAYA Biosciences,” will bring together the unique strengths and capabilities of both organizations, representing a significant leap forward in the healthcare landscape. NAYA Biosciences intends to chart a course that includes expanding revenue streams in the fertility sector, forging revenue-generating pharmaceutical partnerships for therapeutic initiatives, and strategically acquiring complementary technologies and companies.

Merger Details and Leadership Transition:

Under the terms of the agreement, INVO will acquire NAYA Biosciences in an all-stock transaction. Shareholders of NAYA Biosciences will receive 7.3333 shares of INVO for each share of NAYA Biosciences at the time of closing. This arrangement equates to approximately 18,150,000 shares of INVO. Dr. Daniel Teper, the current Chairman & CEO of NAYA Biosciences, will assume the position of Chairman & CEO of the combined company.

The merger is contingent on several closing conditions, including shareholder approval, an estimated $5 million or more (at NAYA’s discretion) in interim private financing in INVO at a premium relative to INVO’s market price at the time of financing (“Interim PIPE”), and a private offering by the combined company at a target price of $5.00 per share.

Valuation and Ownership Structure:

The merger values INVO at $12,373,780 and NAYA at $90,750,000. Subject to the successful execution of the Interim PIPE, post-transaction and prior to the private offering, INVO and NAYA shareholders will have ownership stakes of approximately 12% and 88%, respectively, in the combined company. This carefully structured deal is a testament to the alignment of interests and strategic vision.

A New Era for NAYA Biosciences:

Upon completion of the merger, NAYA Biosciences aims to operate as a NASDAQ-listed consortium comprising agile, disruptive, high-growth companies dedicated to expanding patient access to transformative treatments in three core areas:

  • NAYA Oncology: Focused on pioneering solutions in the field of oncology, NAYA Oncology aims to revolutionize cancer treatments.
  • NAYA Fertility: Committed to advancing fertility care, NAYA Fertility seeks to make assisted reproductive technology (ART) more accessible and inclusive for people worldwide.
  • NAYA Regenerative Medicine: This division is at the forefront of regenerative medicine, with a mission to develop breakthrough treatments that can transform lives.

NAYA Biosciences brings together a unique set of capabilities, including expertise in biology, cell and gene therapy, and artificial intelligence (AI). This expertise, combined with INVO’s established network of fertility clinics (INVO Centers) and the innovative INVOcell® medical device for intravaginal culture, sets the stage for accelerated clinical development and the commercialization of groundbreaking treatments.

About NAYA Biosciences:

NAYA Biosciences is poised to become a leader in the life sciences arena, fostering a cluster of high-growth companies dedicated to advancing oncology, fertility, and regenerative medicine. Leveraging its proficiency in biology, cell and gene therapy, and AI, NAYA Biosciences is on a mission to redefine the landscape of healthcare.

About INVO Bioscience:

INVO Bioscience is a healthcare services fertility company committed to broadening access to assisted reproductive technology (ART) worldwide. The company’s strategy centers on the establishment of dedicated “INVO Centers” offering the INVOcell® and intravaginal culture procedure, acquisition of U.S.-based profitable in vitro fertilization (IVF) clinics, and the distribution of its proprietary technology into existing fertility clinics. INVOcell® represents a pioneering approach to fertilization and early embryo development within the woman’s body, offering a promising alternative to traditional IVF and intrauterine insemination (IUI) treatments.

The merger between INVO Bioscience and NAYA Biosciences represents a major milestone in the life sciences industry, poised to drive innovation and bring transformative treatments to patients worldwide.

Coinbase Confident in Coming US Bitcoin ETF Approval After SEC Court Defeat

Posted on by slightbourne@noblecapitalmarkets.com

Cryptocurrency exchange Coinbase is increasingly confident that a bitcoin exchange-traded fund (ETF) will soon be approved by the US Securities and Exchange Commission (SEC), following the regulator’s recent court loss blocking Grayscale’s bitcoin fund from becoming an ETF.

Paul Grewal, Coinbase’s chief legal officer, told CNBC that the company is “quite hopeful” that pending bitcoin ETF applications will now be approved by the SEC. He highlighted that they should be granted under the law, referring to the Appeals Court ruling that the SEC had no basis to deny Grayscale’s bid to convert its Grayscale Bitcoin Trust (GBTC) into an ETF.

The SEC decided last week not to appeal that court decision, likely clearing the path for a bitcoin ETF to be greenlit in the coming months. While Grewal did not give a timeline, he expressed confidence the SEC will now approve a bitcoin ETF application soon since it cannot arbitrarily reject them following its court loss.

A bitcoin ETF would allow mainstream investors to gain exposure to the cryptocurrency through investing in the fund, without having to directly purchase and hold bitcoin. This could benefit crypto exchanges like Coinbase which are commonly held assets in portfolios aiming to give investors crypto exposure.

However, Grayscale still faces some challenges converting its popular GBTC fund into an ETF. Its parent company Digital Currency Group (DCG), along with Genesis Trading and Gemini crypto exchange, were recently accused in a lawsuit by New York’s attorney general of defrauding investors to the tune of over $1 billion.

Nevertheless, Grewal sounded positive that additional bitcoin ETF products will be coming online soon as the SEC complies with court rulings requiring it to evaluate ETF applications neutrally, solely based on their merits.

Bitcoin has stealthily risen around 72% so far this year, recovering strongly after huge declines in 2022. Driving this comeback is renewed investor interest thanks to expectations of fewer Fed interest rate hikes, and hype building ahead of bitcoin’s next “halving” event in 2024 which will reduce bitcoin mining rewards by 50%, constricting supply.

However, crypto trading volumes have declined recently, as retail investors remain gun-shy after massive crashes of large players like FTX, BlockFi and Three Arrows Capital. The collapses have bred distrust of centralized crypto intermediaries.

Grewal expressed encouragement that “bad actors” in crypto like FTX are being held criminally accountable for alleged multibillion dollar fraud. He believes this will renew consumer interest in cryptocurrency investments.

FTX filed for bankruptcy last year amid a liquidity crunch after investors fled the platform over concerns on its financial stability. Its founder Sam Bankman-Fried was criminally charged by US prosecutors over allegations he defrauded FTX customers and investors out of billions. Bankman-Fried has pleaded not guilty and is currently facing trial.

While the crypto winter persists, Grewal foresees developments on the horizon that will entice investors back into digital assets. The expected approval of a bitcoin ETF could be one catalyst. With blue chip financial giants like Fidelity Investments, CME Group and others applying for bitcoin ETFs, credibility could be lent to crypto as an asset class.

As bitcoin and the broader crypto industry aim to rebuild trust, regulators are focused on rooting out bad actors and holding companies to account for violating securities laws. This could pave the way for institutional investors to gain comfort with crypto, with an ETF providing easy exposure.

If the SEC delivers on expectations and approves a bitcoin ETF application in 2023, it would cap a multi-year effort by the industry and represent a major milestone in mainstream acceptance of cryptocurrencies. For exchanges like Coinbase seeking to broaden their client bases, it could provide a crucial on-ramp for the next generation of crypto investors.

Take a look at Bitcoin Depot, an innovative company that allows users to convert cash into Bitcoin via Bitcoin kiosks distributed throughout North America.

Release – ACCO Brands Corporation Announces Third Quarter 2023 Earnings Webcast

Posted on by aweinsoff@channelchek.com

Research News and Market Data on ACCO

October 20, 2023

LAKE ZURICH, Ill.–(BUSINESS WIRE)– ACCO Brands Corporation (NYSE: ACCO) today announced that it will release its third quarter 2023 earnings after the market close on November 2, 2023. The Company will host a conference call and webcast to discuss the results on November 3 at 8:30 a.m. ET. The webcast can be accessed through the Investor Relations section of www.accobrands.com and will be available for replay.

About ACCO Brands Corporation

ACCO Brands, the Home of Great Brands Built by Great People, designs, manufactures and markets consumer and end-user products that help people work, learn, play and thrive. Our widely recognized brands include AT-A-GLANCE®, Five Star®, Kensington®, Leitz®, Mead®, PowerA®, Swingline®, Tilibra® and many others. More information about ACCO Brands Corporation (NYSE: ACCO) can be found at www.accobrands.com.

Christopher McGinnis
Investor Relations
(847) 796-4320

Kori Reed
Media Relations
(224) 501-0406

Source: ACCO Brands Corporation